Daniela Ampollini

By decision of 14 January 2011, the Court of Turin tackled the issue of the patentability of the intermediate, i.e. the chemical product which represents an obligatory passage of the process of…

In the framework of preliminary injunction proceedings instituted by AstraZeneca against the Italian subsidiary of Stada, EG S.p.A., by decision of 11 - 14 February 2011, the IP Chamber of the Court…

It has been reported by the Italian Generics Association that on 14 March 2011 the European Commission started infringement proceedings against Italy for an alleged breach of Community law related to…

As many readers of this blog already know, last October the Italian Antitrust Authority (Autorità garante della concorrenza e del mercato - AGCM), following a complaint filed by Ratiopharm, started…

Rambus and Micron have been involved in complex patent litigation in Italy since 2000. Things started when, in 2000, Rambus enforced the Italian designation of its patent EP 0525068 on SDRAM memories…

The mere filing of an application for marketing authorization of a generic drug does not constitute an infringing activity., although of a preparatory nature as, aAlthough it is true that the filing…

On 27 October 2010 the Court of Rome issued a decision in the Janssen - Menarini v. EG case concerning the active substance nebivolol. This is one of the few reported cases on enantiomer patents in…

By way of follow up of my many posts on the “intersections” between Italian patent law and the administrative procedures aimed at the authorisation of generic drugs (e.g. here, here and here), it is…

I have already written about the investigation launched last October by the Italian antitrust authority (AGCM) on an alleged abuse of a dominant position by Pfizer in relation to the manner in which…